At present, albendazole is an effective drug to drive ascaris, but it is widely used and often needs to be used repeatedly, because patients will develop drug resistance after using this drug and the recurrence rate is high. The drug is currently sold by GSK.
In the Public Library of Science? An article published in Neglected Tropical Diseases mentioned that Chinese and American scientists are cooperating in the research of tribendimidine, a new insect repellent developed by experts from China Institute of Parasitic Disease Prevention and Control. In 2004, the drug was approved by the US Food and Drug Administration in China, and patients can use it for treatment.
Children and pregnant women are the most susceptible to ascariasis. Ascaris eggs and their larvae usually exist in the soil, and they usually enter the human body through small wounds on the surface of the mouth and skin.
If there is ascaris parasitism in children, it will not only lead to malnutrition, but also affect physical development. Once ascaris enters the eyes, it will also lead to blindness. In addition, repeated infection can also lead to edema of various organs and central nervous system in the body.
Ascariasis is not only common in developing countries, but also in developed countries such as the United States. But people living in temperate/tropical areas are more susceptible to this parasite.
The factors that easily lead to ascariasis are poor hygiene habits, weak immunity, malnutrition, contact with animal feces and so on. If children eat without washing their hands thoroughly after touching soil, they are most likely to get ascariasis.
Recent clinical trials in China and Africa show that tribendimidine can effectively control some roundworms, especially duodenal worms. Experts suggest that those patients who have developed resistance to albendazole can switch to this new drug, and the combined treatment of albendazole and triphenyldiammonium can also enhance the therapeutic effect.